戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d the correlation between the MMSE and those neurocognitive tests.
2 standardized continuous scores on individual neurocognitive tests.
3 uestionnaire and a battery of 6 standardized neurocognitive tests.
4 h HIV worldwide have poor outcomes on formal neurocognitive tests.
5 affected, and the mice performed normally in neurocognitive tests.
6  on the UPSA, the ADCS-ADL, and a battery of neurocognitive tests.
7 s would be associated with deficits found by neurocognitive tests.
8  DTI on a 3.0 Tesla scanner and a battery of neurocognitive tests.
9 aluated by MRI, neurologic examinations, and neurocognitive tests.
10 ng protein B [S100B]); clinical assessments; neurocognitive testing.
11 rwent resting-state functional MRI scans and neurocognitive testing.
12 outinely involved during the above-specified neurocognitive testing.
13 ognitive status characterized from extensive neurocognitive testing.
14 is, 18 years [11 to 42 years]) and completed neurocognitive testing.
15 and were age >/= 18 years were recruited for neurocognitive testing.
16 tcome was based on clinical observations and neurocognitive testing.
17 ells is associated with lower performance on neurocognitive testing.
18 .9 [0.2] years; 208 girls [46.1%]) underwent neurocognitive testing.
19 comes (death or severe disability precluding neurocognitive testing: 19% [68/349] vs 18% [63/351] wit
20                                              Neurocognitive testing; 3-T magnetic resonance imaging.
21 ited no sequelae on physical examination and neurocognitive tests a mean of 6.0 years after infection
22 ive function was assessed using a battery of neurocognitive tests across five domains: memory, orient
23                                              Neurocognitive tests administered were Brief Spanish-Eng
24 multidimensional examination modalities (eg, neurocognitive testing, advanced imaging, biomarkers, an
25 no significant differences in the results of neurocognitive testing among the three treatment groups
26 this retrospective cross-sectional analysis, neurocognitive testing and 3 T brain MRI's were obtained
27                        The authors conducted neurocognitive testing and diffusion tensor imaging in 2
28 th in patients with breast cancer, including neurocognitive testing and functional connectome analysi
29                                              Neurocognitive testing and patient reported outcomes at
30 luations were conducted with age-appropriate neurocognitive testing and quantitative magnetic resonan
31  We evaluated individual performance through neurocognitive tests and by analyzing participants' week
32 d between the two groups and correlated with neurocognitive tests and clinical performance in patient
33                 We administered a battery of neurocognitive tests and recorded electroencephalography
34  worse than non-CNS-treated survivors on all neurocognitive tests and were more likely to have global
35 d routine clinical lab markers, computerized neurocognitive testing, and symptom self-reports.
36 nt repeated structural MRI and comprehensive neurocognitive testing, and they were genotyped for four
37 ecords, representative surveys, computerized neurocognitive tests, and blood samples, Army STARRS and
38 bstantial deficits in learning and memory on neurocognitive tests, and hippocampal slices in which BV
39 d state assessment (Profile of Mood States), neurocognitive tests, and serologic examination.
40 s after their diagnosis, survivors completed neurocognitive testing, another brain MRI, and their par
41                                              Neurocognitive tests are a relatively sensitive measure
42                                              Neurocognitive tests assessing IQ, EF, and episodic memo
43 ted chemotherapy completed protocol-directed neurocognitive testing at the end of therapy.
44 The patients were assessed with a battery of neurocognitive tests at baseline and 12 weeks after begi
45 -resolution structural MRI and comprehensive neurocognitive tests at baseline and 18 months and conti
46 90.5% patients had impairment of one or more neurocognitive tests at baseline.
47              Both groups were administered a neurocognitive test battery and a standardized RCC measu
48 range, 7.8-10.6 years) were assessed using a neurocognitive test battery and parent-report behavioral
49              We administered a comprehensive neurocognitive test battery at baseline and 2 y.
50                                            A neurocognitive test battery included domain-specific ass
51 d examined through the use of a computerized neurocognitive test battery that provided measures of ac
52                                            A neurocognitive test battery was used to assess speed of
53 s, compared the findings to performance on a neurocognitive test battery, and found that N-acetylaspa
54                            Patients received neurocognitive testing before, 1, and 6 months after car
55  high school boys who underwent computerised neurocognitive testing between 2009 and 2018.
56 o examine potential group differences across neurocognitive tests [California Verbal Learning Test (C
57 s of participants; differences on social and neurocognitive tests completed outside the scanner were
58 ctural differences have been associated with neurocognitive testing deficiencies.
59 urocognitive performance, measured by direct neurocognitive tests (Delis-Kaplan Executive Function Sy
60 owever, the performance of the two groups on neurocognitive tests did not significantly differ.
61                                              Neurocognitive tests, driving simulation, and road tests
62 tly associated with worse performance on all neurocognitive tests except that of sustained attention.
63 tly associated with worse performance on all neurocognitive tests except that of verbal memory.
64 confirmed 22q11.2 deletions (N=44) underwent neurocognitive testing following Val(158)Met genotyping
65                                      Monthly neurocognitive testing for memory, executive function, a
66                 A subset of 108 patients had neurocognitive testing for processing speed, memory and
67                                              Neurocognitive testing, functional magnetic resonance im
68 nts (67%) with available long-term follow-up neurocognitive testing had severe impairment in at least
69 us cutoffs, a combination of scores on the 3 neurocognitive tests identified 16 (20%) of the mothers
70 itative magnetic resonance imaging (MRI) and neurocognitive testing in multiple sclerosis (MS) patien
71 ults with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors.
72                                              Neurocognitive testing included assessment of intellectu
73                                              Neurocognitive tests included measures of working memory
74                                              Neurocognitive tests included the Consortium to Establis
75            146 participants (75 PI-mono) had neurocognitive testing (median time after randomization
76 ribe currently used imaging, functional, and neurocognitive testing modalities and to better understa
77 ts underwent different assessments including neurocognitive testing (Montreal Cognitive Assessment [M
78                This knowledge may help guide neurocognitive testing of specific neurological domains
79 tinent users have been found to do poorly on neurocognitive tests of attention and motor skills, both
80 exploratory outcomes included performance on neurocognitive tests of executive function, memory, atte
81 orrelate with poorer performance on selected neurocognitive tests of white matter function.
82                                 Longitudinal neurocognitive test performance in 4 domains (verbal com
83                       Baseline and follow-up neurocognitive test performance was analyzed for all boy
84 izes between familial risk of depression and neurocognitive test performance were largest in TGS; the
85 han 5 years at both CM episode and follow-up neurocognitive testing, plasma tau levels (log10 transfo
86 CM episode and 5 years or older at follow-up neurocognitive testing, plasma tau was associated with w
87                  We observed improvements in neurocognitive test reaction times (p < 0.01) but not ga
88                                              Neurocognitive test results were below normal expectatio
89 RT, we examined the association of NAWM with neurocognitive test results.
90                                              Neurocognitive testing revealed small decrements in some
91                                              Neurocognitive tests revealed impaired performance acros
92 ld TBI and vestibular symptoms had decreased neurocognitive test scores (P < .05) and FA values in th
93 lar convergence insufficiency had diminished neurocognitive test scores (P < .05) and FA values in th
94 elberger State-Trait Anxiety Inventory); and neurocognitive test scores (Rey Auditory Verbal Learning
95                                         Nine neurocognitive test scores captured children's visual-mo
96                                              Neurocognitive test scores of memory, fine motor speed,
97 dings were correlated with symptom severity, neurocognitive test scores, and time to recovery with th
98 ities were correlated with symptom severity, neurocognitive test scores, and time to recovery with th
99 g group had the highest social cognitive and neurocognitive test scores.
100 sures and investigated any correlations with neurocognitive testing scores.
101                                              Neurocognitive testing shows that cognitive impairment i
102                           Low performance on neurocognitive tests specific for dorsolateral prefronta
103 2, 2014, to December 13, 2017, and underwent neurocognitive testing starting March 14, 2015.
104 orate factors known to affect performance on neurocognitive tests, such as education.
105 pe 1 diabetes is associated with deficits on neurocognitive testing that suggest central white matter
106 ialysis, we performed a set of comprehensive neurocognitive tests that included the cognitive domains
107  dementia based on the change over time of 2 neurocognitive tests (the Mini-Mental State Examination
108 d with the CHR phase, measure the ability of neurocognitive tests to predict transition to psychosis,
109 oach highlights the need for development of "neurocognitive" tests to probe the function of component
110 sychological symptom reports, and results of neurocognitive testing using validated instruments were
111                                              Neurocognitive testing was conducted in 350 pediatric le
112                                    Inpatient neurocognitive testing was feasible in pediatric MTBI pa
113                                              Neurocognitive testing was performed at baseline and at
114               In a prospective cohort study, neurocognitive testing was performed in 408 healthy chil
115                    FA maps were obtained and neurocognitive testing was performed in 74 patients with
116 ologic progression scoring that incorporated neurocognitive tests was implemented successfully.
117 , laboratory analysis, physical fitness, and neurocognitive testing were done.
118 dized investigator neurologic assessment and neurocognitive testing were evaluated.
119                                              Neurocognitive tests were administered at baseline and o
120          In 261 patients who underwent CABG, neurocognitive tests were performed preoperatively (at b
121                                         Five neurocognitive tests were used to measure children's vis
122 faction, color vision, sleep parameters, and neurocognitive testing) were assessed at baseline.
123  individuals with UCDs who had comprehensive neurocognitive testing with a cumulative follow-up of 70
124          Patients with mTBI underwent serial neurocognitive testing with Immediate Post-Concussion As
125          Diffusion-tensor imaging and serial neurocognitive testing with the Immediate Post-Concussio

 
Page Top